BEDFORD, Mass.--(BUSINESS WIRE)--Feb. 20, 2019--
Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company
focused on the formulation, development, and commercialization of
innovative therapies for diseases and conditions of the eye, today
announced the dosing of the first patient in a Phase 1 trial of OTX-TKI
(tyrosine kinase inhibitor implant) in patients with wet Age-related
Macular Degeneration (AMD). The first patient was dosed at the Sydney
Retina Clinic in Sydney, Australia.
“We are excited to announce the first patient has been successfully
dosed in our Phase 1 program with OTX-TKI, our tyrosine kinase inhibitor
implant for the treatment of serious retinal disease,” said Michael
Goldstein, M.D., Chief Medical Officer at Ocular Therapeutix. “Our trial
is primarily intended to demonstrate safety, but we will also evaluate
biological activity in patients with increased retinal thickness and
measure whether there are decreases over time. Given that TKI’s act
upstream of VEGF inhibitors, we believe this Phase 1 trial may bring us
one step closer to understanding whether TKI’s may represent a
next-generation treatment for wet AMD and diabetic macular edema.”
The Phase 1 trial is a multi-center, open-label study testing the
safety, durability, and tolerability of OTX-TKI, a bioresorbable
hydrogel fiber implant formulated with a tyrosine kinase inhibitor
delivered by intravitreal injection to patients with wet AMD. The study
will evaluate biological activity by measuring retinal thickness using
standard optical coherence tomography and following visual acuity over
time.
About OTX-TKI (tyrosine kinase inhibitor implant) Intravitreal
Injection
OTX-TKI is a bioresorbable hydrogel formulated with
TKI particles in an injectable fiber that can be delivered through a
small-gauge, sterile injection needle to the back of the eye. OTX-TKI is
designed to deliver drug to the target tissues for a period of up to
nine months, thereby potentially extending the dosing interval from the
one - to two - month frequency needed with the current standard of care.
Preclinical data have demonstrated the ability to deliver TKI to the
posterior segment of the eye with sustained
pharmacokinetic/pharmacodynamic effect for the treatment of VEGF-induced
retinal leakage for a duration of up to twelve months.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc.
is a biopharmaceutical company focused on the formulation, development,
and commercialization of innovative therapies for diseases and
conditions of the eye using its proprietary bioresorbable hydrogel-based
formulation technology. Ocular Therapeutix’s first commercial drug
product, DEXTENZA®, is FDA-approved for the treatment of ocular pain
following ophthalmic surgery. OTX-TP (intracanalicular travoprost
insert) is an intracanalicular insert in Phase 3 clinical development
for the reduction of intraocular pressure in patients with primary
open-angle glaucoma and ocular hypertension. The Company’s earlier stage
assets include OTX-TIC, an extended-delivery intracameral travoprost
implant for the reduction of intraocular pressure in patients with
glaucoma and ocular hypertension, as well as sustained release
intravitreal implants for the treatment of retinal diseases. These
intravitreal implants include OTX-TKI, containing a tyrosine kinase
inhibitor (TKI), and, in collaboration with Regeneron, OTX-IVT, an
extended-delivery protein-based anti-vascular endothelial growth factor
(VEGF) trap. Ocular Therapeutix's first product, ReSure® Sealant, is
FDA-approved to seal corneal incisions following cataract surgery.
Forward Looking Statements
Any statements in this press
release about future expectations, plans, and prospects for the Company,
including the commercialization of ReSure Sealant, DEXTENZA® or any of
the Company’s product candidates; the development and regulatory status
of the Company’s product candidates, such as the Company’s regulatory
submissions for and the timing and conduct of, or implications of
results from, clinical trials of DEXTENZA for the treatment of
post-surgical ocular inflammation and the prospects for approvability of
DEXTENZA for post-surgical ocular inflammation or any other indications,
OTX-TP for the treatment of primary open-angle glaucoma and ocular
hypertension, OTX-TIC for the treatment of primary open-angle glaucoma
and ocular hypertension, OTX-TKI for the treatment of retinal diseases
including wet AMD, and OTX-IVT as an extended-delivery formulation of
the VEGF trap aflibercept for the treatment of retinal diseases
including wet AMD; the Company’s post-approval studies of ReSure®
Sealant and the Company’s ongoing communications with the U.S. Food and
Drug Administration regarding the Company’s appeal of the warning letter
it received regarding ReSure Sealant; the ongoing development of the
Company’s extended-delivery hydrogel depot technology; the potential
utility of any of the Company’s product candidates; the potential
benefits and future operation of the collaboration with Regeneron
Pharmaceuticals, including any potential future payments thereunder; the
sufficiency of the Company’s cash resources and other statements
containing the words "anticipate," "believe," "estimate," "expect,"
"intend", "goal," "may", "might," "plan," "predict," "project,"
"target," "potential," "will," "would," "could," "should," "continue,"
and similar expressions, constitute forward-looking statements within
the meaning of The Private Securities Litigation Reform Act of 1995.
Actual results may differ materially from those indicated by such
forward-looking statements as a result of various important factors.
Such forward-looking statements involve substantial risks and
uncertainties that could cause the Company’s clinical development
programs, future results, performance or achievements to differ
significantly from those expressed or implied by the forward-looking
statements. Such risks and uncertainties include, among others, those
related to the timing and costs involved in commercializing ReSure
Sealant, DEXTENZA or any product candidate that receives regulatory
approval, including the conduct of post-approval studies, the ability to
retain regulatory approval of ReSure Sealant, DEXTENZA or any product
candidate that receives regulatory approval, the initiation, timing and
conduct of clinical trials, availability of data from clinical trials
and expectations for regulatory submissions and approvals, the Company’s
scientific approach and general development progress, the availability
or commercial potential of the Company’s product candidates, the
sufficiency of cash resources, the Company’s existing indebtedness, the
ability of the Company’s creditors to accelerate the maturity of such
indebtedness upon the occurrence of certain events of default, the
outcome of the Company’s ongoing legal proceedings and need for
additional financing or other actions and other factors discussed in the
“Risk Factors” section contained in the Company’s quarterly and annual
reports on file with the Securities and Exchange Commission. In
addition, the forward-looking statements included in this press release
represent the Company’s views as of the date of this release. The
Company anticipates that subsequent events and developments will cause
the Company’s views to change. However, while the Company may elect to
update these forward-looking statements at some point in the future, the
Company specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as representing the
Company’s views as of any date subsequent to the date of this release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190220005503/en/
Source: Ocular Therapeutix
Investors
Ocular Therapeutix
Donald Notman
Chief
Financial Officer
dnotman@ocutx.com
or
Westwicke
Partners
Chris Brinzey
Managing Director
chris.brinzey@westwicke.com
Media
Ocular Therapeutix
Scott Corning
Senior Vice
President, Commercial
scorning@ocutx.com
